PCM
SGYP

Prelude Capital Management’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Prelude Capital Management’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-6,000
Closed -$32K – 2292
2014
Q1 		$32K Buy
+6,000
New +$33.6K ﹤0.01% 1566

Other funds holding SGYP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Prelude Capital Management's SGYP Position: Q1 2018 in Review

Prelude Capital Management sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2018, closing a stake of 251,341 shares — an estimated $560K sold.

Prelude Capital Management first reported a position in SGYP in Q2 2013 and held it in 16 quarters. The position peaked at $2.33M in Q1 2017. 147 funds tracked by Wall St. Rank hold SGYP as of Q1 2018.

  • Prelude Capital Management reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2018 after selling out during the quarter.
  • Prelude Capital Management sold 251,341 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2018, an estimated $560K.
  • Prelude Capital Management first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 16 quarters.
  • Prelude Capital Management's Synergy Pharmaceuticals, Inc Common Stock position peaked at $2.33M in Q1 2017.
  • 147 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2018.

Based on Prelude Capital Management's 13F filing for Q1 2018, filed 15 May 2018.